中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
20期
102-103
,共2页
卡培他滨%奥沙利铂%晚期结肠癌%联合化疗
卡培他濱%奧沙利鉑%晚期結腸癌%聯閤化療
잡배타빈%오사리박%만기결장암%연합화료
Xeloda%Oxaliplatin%Advanced colon cancer%Combination chemotherapy
目的：观察卡培他滨加用奥沙利铂联合治疗晚期结肠癌的临床疗效和毒副作用。方法给予36例晚期结肠癌患者卡培他滨1250 mg/m2日两次口服，第1～14 d，奥沙利铂130 mg/m2，第1 d静滴3 h，21 d为1个疗程周期，2个疗程以上做疗效评价。结果36例均可评价疗效， CR3例，PR18例，RR58.3%；毒副作用主要为恶心、呕吐、腹泻、口腔溃疡、末梢神经异常及骨髓抑制，大多数为Ⅰ～Ⅱ度。结论卡培他滨加用奥沙利铂联合治疗晚期结肠癌临床疗效肯定，且患者耐受性较好。
目的：觀察卡培他濱加用奧沙利鉑聯閤治療晚期結腸癌的臨床療效和毒副作用。方法給予36例晚期結腸癌患者卡培他濱1250 mg/m2日兩次口服，第1～14 d，奧沙利鉑130 mg/m2，第1 d靜滴3 h，21 d為1箇療程週期，2箇療程以上做療效評價。結果36例均可評價療效， CR3例，PR18例，RR58.3%；毒副作用主要為噁心、嘔吐、腹瀉、口腔潰瘍、末梢神經異常及骨髓抑製，大多數為Ⅰ～Ⅱ度。結論卡培他濱加用奧沙利鉑聯閤治療晚期結腸癌臨床療效肯定，且患者耐受性較好。
목적：관찰잡배타빈가용오사리박연합치료만기결장암적림상료효화독부작용。방법급여36례만기결장암환자잡배타빈1250 mg/m2일량차구복，제1～14 d，오사리박130 mg/m2，제1 d정적3 h，21 d위1개료정주기，2개료정이상주료효평개。결과36례균가평개료효， CR3례，PR18례，RR58.3%；독부작용주요위악심、구토、복사、구강궤양、말소신경이상급골수억제，대다수위Ⅰ～Ⅱ도。결론잡배타빈가용오사리박연합치료만기결장암림상료효긍정，차환자내수성교호。
Objective To observe the clinical efficacy and tolerability of xeloda with oxaliplatin on advanced colon cancer.MethodsThirty-six patients with advanced colon cancer were treated with xeloda 1 250 mg/m2 po on the first day to the 14 day and oxaliplatin 130 mg/m2 ivgtt,on the first 21 days for a period of treatment cycle. More than 2 courses of curative effect were evaluated. Results Thirty-six cases evaluated curative effect,CR 3 cases,19 cases of PR. The overal response rate was 61.1%. Toxicity mainly were grade Ⅰ~Ⅱ,including nausea vomiting,diarrhea,oral ulcer,bone marrow suppression,and peripheral nerve abnormalities.Conclusion Xeloda regimen combined with oxaliplatin into curative effect on treatment of advanced colorectal cancer,and patient tolerance is good.
